YOUR BUSINESS AUTHORITY
Springfield, MO
Tomo Drug Testing announced its second acquisition of the year and in company history.
Following a July purchase in Indiana — the company’s first buyout — Tomo Drug Testing followed up with the Aug. 1 acquisition of Tulsa, Oklahoma-based Knox Laboratory, according to a news release issued late last week. The financial terms of the deal were undisclosed.
“This addition will increase and diversify our regional presence, and Knox’s talented staff brings added depth that we’re thrilled to have as part of our Tomo family,” said Mickey Moore, owner and CEO of Tomo Drug Testing, in the release.
Knox Laboratory’s offices in Tulsa and Bartlesville, Oklahoma, are scheduled to take on the Tomo Drug Testing name on Jan. 1. With 15 employees, the locations serve more than 1,000 clients.
The acquisition came about when Pennington Capital LLC — which had owned Knox Laboratory through investment group PAHC II — approached Tomo Drug Testing in late 2018, according to the release.
“I am pleased to see all the reasons why Tomo is excited about Knox, from the quality of their customer group and operating excellence of their team to the value that Tomo will bring to the equation,” Pennington Capital Managing Partner Lane Pennington said in the release.
Tomo Drug Testing last month announced the purchase of Indianapolis-based Drug and Alcohol Testing LLC, its first ever acquisition.
Project work in Springfield corridor will continue into 2031.
Thanksgiving staple recalled at Costco
HBA of Greater Springfield executive officer to retire
Warren Buffett donates $5.5B worth of Berkshire Hathaway shares
Transportation officials discuss $471M Forward 44 initiative
Monday Morning Business Leads: Nov. 16, 2026
Ozarks Farm Stop remains open after car crashes into building
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.